Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health

被引:0
|
作者
Yitian Zhou
Volker M. Lauschke
机构
[1] Karolinska Institutet,Department of Physiology and Pharmacology
[2] Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology,undefined
来源
Human Genetics | 2022年 / 141卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Both safety and efficacy of medical treatment can vary depending on the ethnogeographic background of the patient. One of the reasons underlying this variability is differences in pharmacogenetic polymorphisms in genes involved in drug disposition, as well as in drug targets. Knowledge and appreciation of these differences is thus essential to optimize population-stratified care. Here, we provide an extensive updated analysis of population pharmacogenomics in ten pharmacokinetic genes (CYP2D6, CYP2C19, DPYD, TPMT, NUDT15 and SLC22A1), drug targets (CFTR) and genes involved in drug hypersensitivity (HLA-A, HLA-B) or drug-induced acute hemolytic anemia (G6PD). Combined, polymorphisms in the analyzed genes affect the pharmacology, efficacy or safety of 141 different drugs and therapeutic regimens. The data reveal pronounced differences in the genetic landscape, complexity and variant frequencies between ethnogeographic groups. Reduced function alleles of CYP2D6, SLC22A1 and CFTR were most prevalent in individuals of European descent, whereas DPYD and TPMT deficiencies were most common in Sub-Saharan Africa. Oceanian populations showed the highest frequencies of CYP2C19 loss-of-function alleles while their inferred CYP2D6 activity was among the highest worldwide. Frequencies of HLA-B*15:02 and HLA-B*58:01 were highest across Asia, which has important implications for the risk of severe cutaneous adverse reactions upon treatment with carbamazepine and allopurinol. G6PD deficiencies were most frequent in Africa, the Middle East and Southeast Asia with pronounced differences in variant composition. These variability data provide an important resource to inform cost-effectiveness modeling and guide population-specific genotyping strategies with the goal of optimizing the implementation of precision public health.
引用
收藏
页码:1113 / 1136
页数:23
相关论文
共 50 条
  • [21] Pharmacogenomics and public health: implementing 'populationalized' medicine
    Mette, Lindsey
    Mitropoulos, Konstantinos
    Vozikis, Athanassios
    Patrinos, George P.
    PHARMACOGENOMICS, 2012, 13 (07) : 803 - 813
  • [22] Population-level pharmacogenomics for precision drug development in dementia
    Cacabelos, Ramon
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 163 - 188
  • [23] OPPORTUNITIES IN PUBLIC HEALTH
    IRWIN, VD
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1946, 33 (01): : 54 - 55
  • [24] Editorial: DNA-based population screening for precision public health
    Milko, Laura V. V.
    Khoury, Muin J. J.
    FRONTIERS IN GENETICS, 2022, 13
  • [25] Population-scale genomics-Enabling precision public health
    Sivadas, Ambily
    Scaria, Vinod
    ADVANCES IN GENETICS, VOL 103, 2019, 103 : 119 - 161
  • [26] Pharmacogenomics Tools for Precision Public Health and Lessons for Low- and Middle-Income Countries: A Scoping Review
    Borbon, Angelica
    Briceno, Juan Carlos
    Valderrama-Aguirre, Augusto
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2025, 18 : 19 - 34
  • [27] Dissemination, Implementation, and Improvement Science Research in Population Health: Opportunities for Public Health and CTSAs
    Kuo, Tony
    Gase, Lauren N.
    Inkelas, Moira
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2015, 8 (06): : 807 - 813
  • [28] Precision Public Health for the Era of Precision Medicine
    Khoury, Muin J.
    Iademarco, Michael F.
    Riley, William T.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2016, 50 (03) : 398 - 401
  • [29] Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine
    Ji, Yuan
    Si, Yue
    McMillin, Gwendolyn A.
    Lyon, Elaine
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2018, 18 (05) : 411 - 421
  • [30] NICE Update NICE public health update
    Killoran, Amanda
    Chatterton, Hilary
    Younger, Tricia
    Ellis, Simon
    Owen, Lesley
    JOURNAL OF PUBLIC HEALTH, 2012, 34 (03) : 471 - 472